Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $27.37 million for the quarter.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Stoke Therapeutics Stock Down 2.4 %
Shares of Stoke Therapeutics stock traded down $0.24 on Friday, hitting $9.63. 640,908 shares of the company were exchanged, compared to its average volume of 710,291. The company has a 50-day moving average price of $7.90 and a 200 day moving average price of $10.18. The stock has a market capitalization of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.20. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $17.58.
Insiders Place Their Bets
In other news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock valued at $143,332 over the last 90 days. 11.30% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Chardan Capital reiterated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and an average target price of $24.67.
Get Our Latest Stock Analysis on Stoke Therapeutics
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Read More

Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.